The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Rise In Market Size Of The Systemic Aspergillosis And Systemic Candidiasis Market During The Forecast Period?
The systemic aspergillosis and systemic candidiasis market has experienced steady expansion in recent years. This market is expected to increase from $7.57 billion in 2025 to $7.94 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.9%. The historical growth can be attributed to several factors such as the increasing immunocompromised patient populations, the rising prevalence of invasive fungal infections, the availability of azole and amphotericin formulations, the expansion of hospital intensive care units, and improved diagnostic awareness.
The systemic aspergillosis and systemic candidiasis market is projected to experience robust expansion over the coming years. This market is set to reach $9.76 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. The anticipated growth during this period stems from factors such as the increasing creation of new antifungal agents, an escalating emphasis on managing antifungal resistance, the broadening of targeted antifungal treatments, rising investments into infectious disease research, and a greater uptake of combination treatment plans. Key developments expected within the forecast timeframe involve a growing embrace of advanced antifungal solutions, a heightened concentration on the early detection of systemic fungal infections, the widening use of combined antifungal treatment strategies, an increasing need for hospital-based critical care antifungals, and enhanced surveillance of drug resistance patterns.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12148&type=smp
What Core Drivers Are Transforming The Systemic Aspergillosis And Systemic Candidiasis Market?
The anticipated rise in fungal disease occurrences is projected to drive expansion within the systemic aspergillosis and systemic candidiasis market in the future. Fungal diseases are defined as infections stemming from fungi, capable of impacting diverse areas of the body and leading to a range of symptoms and complications. Examples of such conditions encompass cutaneous skin infections, respiratory infections, and systemic infections. Treatment for fungal diseases typically involves antifungal medications, including oral azoles, voriconazole, and liposomal amphotericin B. As an illustration, the Uk Health Security Agency, a UK-based government entity, reported that in 2023, the incidence of yeast-related bloodstream infections in England saw a 4% increase compared to 2022. Consequently, the rising prevalence of fungal diseases is a key factor fueling the expansion of the systemic aspergillosis and systemic candidiasis market.
How Is The Systemic Aspergillosis And Systemic Candidiasis Market Examined Through Segment Analysis?
The systemic aspergillosis and systemic candidiasis market covered in this report is segmented –
1) By Type: Systemic Oral Azoles, Voriconazole, Liposomal Amphotericin B, Topical Antifungal Agents, Other Types
2) By Application: Allergic Bronchopulmonary Aspergillosis (ABPA), Chronic Pulmonary Aspergillosis (CPA), Gastrointestinal Candidiasis, Genitourinary Tract Candidiasis, Other Applications
3) By End User: Clinic, Hospital, Other End Users
Subsegments:
1) By Systemic Oral Azoles: Fluconazole, Itraconazole, Posaconazole, Voriconazole
2) By Voriconazole: Voriconazole Tablets, Voriconazole Injection
3) By Liposomal Amphotericin B: Liposomal Amphotericin B For Systemic Aspergillosis, Liposomal Amphotericin B For Systemic Candidiasis
4) By Topical Antifungal Agents: Topical Azoles, Topical Polyenes, Topical Allylamines
5) By Other Types: Echinocandins, Antifungal Combination Therapies, Other Emerging Antifungal Agents
Which Trends Are Influencing The Expansion Of The Systemic Aspergillosis And Systemic Candidiasis Market?
Leading companies active in the syphilis immunoassay diagnostics market are dedicated to developing inventive solutions, such as rapid syphilis tests, to boost the effectiveness and precision of syphilis detection. Rapid syphilis tests are straightforward, point-of-care instruments that identify syphilis antibodies in blood or bodily fluids within minutes, allowing for prompt diagnosis and early intervention. For example, in February 2023, Chembio Diagnostics Inc., a US-based point-of-care diagnostics company focusing on infectious diseases, secured a CLIA waiver from the FDA for its DPP HIV-Syphilis System. The DPP HIV-Syphilis System is a dual rapid test designed for the concurrent detection of antibodies to HIV 1/2 and Treponema pallidum, the bacterium that causes syphilis. This quick, 15-minute test is intended to enhance diagnosis and treatment, particularly in avoiding mother-to-child transmission of syphilis and diminishing the risk of acquiring HIV among those affected by syphilis.
Which Organizations Are Operating Within The Systemic Aspergillosis And Systemic Candidiasis Market?
Major companies operating in the systemic aspergillosis and systemic candidiasis market are Pfizer Inc, Merck & Co. Inc, AbbVie Inc, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Abbott Laboratories, Sanofi S.A, GlaxoSmithKline PLC, Gilead Sciences Inc, Astellas Pharma Inc, Matinas BioPharma Holdings Inc, Shionogi & Co. Ltd, Cipla Limited, Basilea Pharmaceutica Ltd, Cidara Therapeutics Inc, Entasis Therapeutics Inc, F2G Ltd, Mycovia Pharmaceuticals Inc, ContraFect Corporation, Enzon Pharmaceutical Inc, Pacgen Life Science Corporation, Biosergen AS
Access The Complete Systemic Aspergillosis And Systemic Candidiasis Market Report:
Which Region Contributes The Most To The Systemic Aspergillosis And Systemic Candidiasis Market?
North America was the largest region in the systemic aspergillosis and systemic candidiasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the systemic aspergillosis and systemic candidiasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Systemic Aspergillosis And Systemic Candidiasis Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/customise?id=12148&type=smp
Browse Through More Reports Similar to the Global Systemic Aspergillosis And Systemic Candidiasis Market 2026, By The Business Research Company
Aspergillosis Treatment Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/aspergillosis-treatment-global-market-report
Candidiasis Therapeutics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/candidiasis-therapeutics-global-market-report
Invasive Fungal Infections Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/invasive-fungal-infections-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model